7 Mitochondrial DNA Mutations Phenocopy VHL Loss to Drive Non-Clear Cell RCC Authors: Ziad Bakouny, Rachel Saxe, Neil Ruthen, Sonia Boscenco, Ji-Young Kim, Ruobing Cui, Andrea Lopez Sanmiguel, Ritesh Kotecha, Maria Carlo, Martin Voss, A Ari Hakimi, Robert Motzer, Payam Gammage, Ed Reznik, Craig Thompson Published: 2026 ABSTRACT AbstractBackgroundLoss of VHL, the primary driver of clear cell renal cell carcinoma (ccRCC), promotes aerobic glycolysis and suppresses oxidative phosphorylation (OxPhos). In contrast, non-clear cell RCC (non-ccRCC) comprises heterogeneous tumors lacking shared nuclear drivers. Mitochondrially-encoded electron transport chain (ETC) genes encoding for complex I, required for OxPhos, have been recently reported to be recurrently mutated across cancers. Here, we show that mitochondrial DNA (mtDNA) mutations in non-ccRCC phenocopy VHL loss, converging on a shared metabolic program to drive a stem-like transcriptional state.MethodsmtDNA mutations were called in samples with sufficient coverage ( > =5 reads across >90% of the mitochondrial genome) in TCGA (N = 3,265; N = 324 RCC) and the institutional MSK-IMPACT cohort (N = 22,252; N = 568 RCC). Isogenic cell lines (ACHN, 786O, HEK293T) harboring pathogenic complex I mutations (m.11696G>A) were generated using DddA-derived cytidine base editors (ddCBEs) at different levels of heteroplasmy. Metabolic phenotyping was performed using Gas Chromatography (GC/MS) and Liquid Chromatography–Mass Spectrometry (LC/MS) as well as Seahorse and YSI assays. Single cell multi-omics was performed with DOGMA-seq with mtDNA variant calling performed using mgatk.ResultsAcross all cancer types in TCGA, RCC tumors were among the most enriched in ETC truncating mutations. These mutations most commonly affected mitochondrial components of complex I and were enriched to high levels of heteroplasmy. VHL-driven ccRCC was relatively depleted in these mutations compared to other subtypes (ccRCC: 8.6%, chRCC: 20.0%, pRCC: 34.0%) (Figure 1a). These results were independently replicated in the MSK-IMPACT cohort (data not shown). ACHNm.11696G>A heteroplasmic cells displayed decreased oxygen consumption rates (Figure 1b), increased glucose consumption and lactate production (Figure 1c), phenocopying the effect of VHL KO (data not shown). These metabolic changes led to an increase in the 2-hydroxyglutarate/alpha-ketoglutarate (2HG/aKG) ratio with increasing heteroplasmy (Figure 1d), complex I pharmacologic inhibition (Figure 1e), and VHL KO (Figure 1f). This increase in 2HG was entirely accounted for by the L-enantiomer of 2HG (Figure 1g) and was consistently found in RCC tumors compared to normal kidney (Figure 1h), with the extent of elevation being most pronounced in tumors with sarcomatoid/rhabdoid features (Figure 1i). To evaluate the effect of heteroplasmy on transcriptional state, we performed DOGMA-seq on ACHNm.11696G>A with 76% bulk heteroplasmy (Figure 1j); the wide single-cell distribution of heteroplasmy (Figure 1k) allowed us to evaluate the correlation of heteroplasmy with transcriptional state at the single-cell level. We consistently found that heteroplasmy associated with an increase in OCT4, NANOG, and SOX2 target genes consistent with a stem-like signature (Figure 1l).ConclusionsmtDNA mutations are very common in non-ccRCC and phenocopy the metabolic effects of VHL loss in ccRCC. Both mtDNA mutations and VHL loss lead to an increase in the 2HG/aKG ratio, which has been shown to lead to a block in differentiation via the inhibition of aKG-dependent dioxygenases (PMIDs: 33092942; 26212717; 31534224). Consistently, we find that increasing heteroplasmy associates with a stem-like signature. These findings nominate mtDNA mutations as a shared driver across non-ccRCC subtypes.DOD CDMRP Fundingyes7 Figure 1Mitochondrial DNA mutations in RCC drive a stem-like transcriptional program by phenocopying VHL loss. (a) Truncating mtDNA mutations are common in non-ccRCC; (b) Isogenic mtDNA mutations lead to decreased oxygen consumption rate; (c) YSI assays showing increased glucose consumption and lactate production; heteroplasmy (d), complex I inhibition (e), and VHL KO (f) lead to increased 2HG/aKG ratio; (g) 2HG elevation is entirely accounted for by the L-enantiomer; (h) 2HG elevation is a hallmark of RCC tumors; (i) sarcomatoid/rhabdoid tumors have the highest amount of 2HG; (j-l) DOGMA-seq experiment showing increased OCT4 target genes with increasing heteroplasmy.Ctrl: Control, Pyr: Pyruvate, Rot: Rotenone, 2HG: 2-hydroxyglutarate, aKG: alpha-ketoglutarate, S/R: Sarcomatoid/rhabdoid